Dominik Karres

Dominik received his medical degree and MD in paediatric drug development from the University Erlangen/ Nuremberg (Germany). He trained in Germany in paediatric oncology (University Hospital Muenster) and worked in Germany and the UK (Royal Marsden Hospital/ Institute of Cancer Research UK) in paediatric oncology drug development. In 2014 he joined the UKs medicines regulatory agency (MHRA) with positions in the Licensing and Post-marketing Division as accredited assessor and national expert to the European Medicines Agency, before joining the EMAs Paediatric Medicines Office in 2018. 

With his clinical and regulatory background, he is now involved at the agency in regulatory science related aspects concerning paediatric oncology drug development. In this capacity he is also the EMAs nominee to the ACCELERATE Steering committee, a multi-stakeholder platform aiming to facilitate the acceleration of science driven developments of paediatric oncology drugs through global cooperation and collaboration. Dominik has (co)-authored several scientific articles and policy pieces in peer-reviewed journals on the topic of paediatric oncology drug development.